Cargando…

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer

INTRODUCTION: The 21-gene Recurrence Score(®) assay (Oncotype DX(®), Genomic Health, Inc.) is a validated predictor of recurrence risk/chemotherapy benefit in patients with estrogen receptor-positive (ER+) early-stage breast cancer treated with endocrine therapy. The Prosigna(®) assay (NanoString Te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarado, Michael D., Prasad, Che, Rothney, Megan, Cherbavaz, Diana B., Sing, Amy P., Baehner, Frederick L., Svedman, Christer, Markopoulos, Christos J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679783/ https://www.ncbi.nlm.nih.gov/pubmed/26610383 http://dx.doi.org/10.1007/s12325-015-0269-2

Ejemplares similares

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
por: Nielsen, Torsten, et al.
Publicado: (2014)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay
por: Hurson, Amber N., et al.
Publicado: (2023)

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
por: Swain, Sandra M., et al.
Publicado: (2015)

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
por: Lundgren, Christine, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
por: Jensen, Maj-Britt, et al.
Publicado: (2018)

Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
por: Ohnstad, Hege O., et al.
Publicado: (2017)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression
por: Kwan, Marilyn L, et al.
Publicado: (2015)

Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes
por: Mathews, James C., et al.
Publicado: (2019)

Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
por: Ochoa, Soledad, et al.
Publicado: (2020)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments
por: Hu, Ying, et al.
Publicado: (2013)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(®) Test in the management of early-stage breast cancers
por: Hequet, Delphine, et al.
Publicado: (2017)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
por: Bastien, Roy RL, et al.
Publicado: (2012)

Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes
por: Liu, Rong, et al.
Publicado: (2016)

Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test
por: Jakubowski, Debbie M., et al.
Publicado: (2020)

The LEPSIS Pam-File
por: DELPHI Collaboration
Publicado: (1982)

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
por: Phakathi, Boitumelo, et al.
Publicado: (2023)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
por: Perez, Edith A., et al.
Publicado: (2015)

Modifications to the LEPSIM Pam-File
por: DELPHI Collaboration
Publicado: (1982)

El Pim-pam-pum
por: Ionesco, Eugène

Cannot write session to /tmp/vufind_sessions/sess_durqaoalukb0dmqlugnnbh1kbi